# US 2025/0019419 A1 · Production method for product and product

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0019419 A1
- Document ID: US20250019419A1
- Status: Published application
- Kind: A1
- Application number: 18/898,929
- Filed: 2024-09-27
- Published: 2025-01-16
- Earliest claimed: 2022-03-28
- Assignees: FUJIFILM Corporation
- Applicants: FUJIFILM Corporation
- Inventors: Shinichi NAKAI; Atsushi INADA; Hiroshi SAKUYAMA; Naoto TAKAHASHI
- Web page: https://patentgrep.com/patent/US20250019419A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C12N 2500/00: Specific components of cell culture medium
- C12N 2500/34: Sugars
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An object of the present invention is to provide a method in which the amount of mannose 5 in a product can be reduced in the production method for the product by cell culture, and a product that is produced by the method. According to the present invention, there is provided a production method for a product, including culturing cells in a culture container, in which the culturing is a perfusion culture method, Expressions (1) to (5) are satisfied in a production period of a product after reaching a target viable cell density, a variation of VCD during the production period is ±20% or less with respect to an average viable cell density during the production period, and a variation of VCV during the production period is ±20% or less with respect to an average value of the VCV during the production period. 0≤Gln-C≤2.5 Expression (1) 0.5≤Gluc-C≤8.0 Expression (2) 1.0≤NH4-C≤8.0 Expression (3) 50≤VCD≤300 Expression (4) 0.6×105≤VCV≤4.0×105 Expression (5) The meanings of the symbols in the expressions are as defined in the present specification.

## Claims

### Claim 1

A production method for a product, comprising:
culturing cells in a culture container,
wherein the culturing is a perfusion culture method,
Expressions (1) to (5) are satisfied in a production period of a product after reaching a target viable cell density,
a variation of VCD during the production period is ±20% or less with respect to an average viable cell density during the production period, and
a variation of VCV during the production period is ±20% or less with respect to an average value of the VCV during the production period,
0≤Gln-C≤2.5 Expression (1)
0.5≤Gluc-C≤8.0 Expression (2)
1.0≤NH4-C≤8.0 Expression (3)
50≤VCD≤300 Expression (4)
0.6×105≤VCV≤4.0×105 Expression (5)
in the expressions, Gln-C indicates a glutamine concentration [mmol/L] in a culture solution, Gluc-C indicates a glucose concentration [g/L] in the culture solution, NH4-C indicates an ammonia concentration [mmol/L] in the culture solution, VCD indicates a viable cell density [×106 cells/mL], VCV indicates VCD×π/6×Cd3 [×106 μm3/mL], and Cd indicates an average diameter [μm] of viable cells.

### Claim 2 (depends on 1)

The production method for a product according to claim 1,
wherein the culture solution is bled such that the variation of VCD during the production period is ±20% or less with respect to the average viable cell density during the production period.

### Claim 3 (depends on 2)

The production method for a product according to claim 2,
wherein in the bleeding, the culture solution is bled while an electrostatic capacity of the culture solution is subjected to in-line measurement.

### Claim 4 (depends on 3)

The production method for a product according to claim 3,
wherein the bleeding is automatically controlled.

### Claim 5 (depends on 3)

The production method for a product according to claim 3,
wherein a variation of the electrostatic capacity of the culture solution, where the electrostatic capacity is subjected to in-line measurement, is ±20% or less with respect to an average value of an electrostatic capacity during the production period.

### Claim 6 (depends on 3)

The production method for a product according to claim 3,
wherein the bleeding includes:
(i) setting an electrostatic capacity serving as a target;
(ii) setting a weight control value of the culture container;
(iii) measuring the electrostatic capacity of the culture solution at a period of 0.1 seconds or less;
(iv) driving a pump for draining the culture solution at a rate of 0.3 vvd to 3 vvd in a case where the electrostatic capacity of the culture solution exceeds the target (here, vvd means “volume of drained culture solution/volume of culture solution/day”); and
(v) automatically supplying a culture medium to the culture container while measuring a mass of the culture solution such that a variation of a liquid amount of the culture solution is within 10%; and
(vi) stopping the pump for draining the culture solution in a case where the electrostatic capacity of the culture solution is smaller than the target by 0.01% or more.

### Claim 7 (depends on 1)

The production method for a product according to claim 1,
wherein Expression (6) is satisfied in the production period,
2≤LDH/VCD≤40 Expression (6)
in the expression, LDH indicates a concentration [U/L] of lactate dehydrogenase in the culture solution, and VCD indicates a viable cell density [×106 cells/mL].

### Claim 8 (depends on 1)

The production method for a product according to claim 1,
wherein the cell is an animal cell.

### Claim 9 (depends on 1)

The production method for a product according to claim 1,
wherein the cell is a cell that produces a protein.

### Claim 10 (depends on 1)

The production method for a product according to claim 1,
wherein the cell is a cell that produces an antibody.

### Claim 11 (depends on 1)

The production method for a product according to claim 1,
wherein the cell is a CHO cell.

### Claim 12 (depends on 1)

The production method for a product according to claim 1,
wherein Expressions (2B) is satisfied in a production period of a product after reaching a target viable cell density,
1.5≤Gluc-C≤5.0 Expression (2B)
in the expressions, Gluc-C indicates a glucose concentration [g/L] in the culture solution.

### Claim 13 (depends on 1)

A product that is produced by the production method for a product according to claim 1.

### Claim 14 (depends on 13)

The product according to claim 13, wherein the proportion of Mannose 5 in total N-type sugar chains in the production is 7% or less.
